Palmitoylethanolamide

Study explores power of Palmitoylethanolamide in managing pain

17-Oct-2022 By Asia Sherman

Palmitoylethanolamide (PEA) reduces sensitivity to pain in the central and peripheral nervous systems and increases pain modulation, says a recent study from Austrian researchers.

PEA may improve outcomes for Covid-19: Study

19-Sep-2022 By Nicola Gordon-Seymour

Palmitoylethanolamide (PEA) may reduce inflammation and optimise immune responses to infectious conditions such as Covid-19, according to researchers in the USA.

Palmitoylethanolamide a viable, non-toxic alternative to cannabidiols, say scientists

19-Jan-2022 By Nicola Gordon-Seymour

Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’

CBD-alternative? Review shows PEA targets similar pathways, ‘but safer and legal’

15-Dec-2021 By Tingmin Koe

An ingredient commonly isolated from soybeans, peanuts, and egg yolks, has been shown in a recent review to act in similar pathways as cannabidiol (CBD), with researchers highlighting that it was a safer and legally recognised alternative.

PEA supplements may help people fall asleep and boost cognition on waking: Study

20-Sep-2021 By Stephen Daniells

Eight weeks of supplementation with palmitoylethanolamide, an endocannabinoid-like molecule, may improve sleep measures in healthy adults, according to results of a double-blind, randomized, placebo-controlled study.

PEA supplements may reduce joint discomfort: Study

03-May-2021 By Stephen Daniells

Two weeks of supplementation with palmitoylethanolamide, an endocannabinoid-like molecule with potent anti-inflammatory properties, may reduce joint discomfort and improving quality of life in adults, says a new study.